Clinical trial
CD19-targeting CAR T Cells for Refractory B Cell Lymphoma
NCT02547948 is registered in ClinicalTrials.gov with Fuda Cancer Hospital, Guangzhou as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- CD19-targeting CAR T Cells for Refractory B Cell Lymphoma
- Lead sponsor
- Fuda Cancer Hospital, Guangzhou
- Phase
- Phase 1/2
- Overall status
- Withdrawn
- Start date
- September 30, 2015
- Completion date
- August 15, 2016
- Enrollment
- 0 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
b cell lymphoma